0000950170-24-069608.txt : 20240605
0000950170-24-069608.hdr.sgml : 20240605
20240605211540
ACCESSION NUMBER: 0000950170-24-069608
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240603
FILED AS OF DATE: 20240605
DATE AS OF CHANGE: 20240605
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lyon Joseph Douglas
CENTRAL INDEX KEY: 0001817838
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-50679
FILM NUMBER: 241023679
MAIL ADDRESS:
STREET 1: C/O CORCEPT THERAPEUTICS INCORPORATED
STREET 2: 149 COMMONWEALTH DRIVE
CITY: MENLO PARK
STATE: CA
ZIP: 94025
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CORCEPT THERAPEUTICS INC
CENTRAL INDEX KEY: 0001088856
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 770487658
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 149 COMMONWEALTH DRIVE
CITY: MENLO PARK
STATE: CA
ZIP: 94025
BUSINESS PHONE: 650.688.8803
MAIL ADDRESS:
STREET 1: 149 COMMONWEALTH DRIVE
CITY: MENLO PARK
STATE: CA
ZIP: 94025
4
1
ownership.xml
4
X0508
4
2024-06-03
0001088856
CORCEPT THERAPEUTICS INC
CORT
0001817838
Lyon Joseph Douglas
C/O CORCEPT THERAPEUTICS INCORPORATED
149 COMMONWEALTH DRIVE
MENLO PARK
CA
94025
false
true
false
false
See Remarks
true
Common Stock
2024-06-03
4
M
false
5000
11.35
A
12314
D
Common Stock
2024-06-03
4
S
false
5000
30.1832
D
7314
D
Common Stock
2024-06-03
4
F
false
488
30.17
D
6826
D
Common Stock
2024-06-03
4
A
false
1232
31.30
A
8058
D
Common Stock
2024-06-03
4
A
false
1232
0.00
A
9290
D
Stock option (right to buy)
11.35
2024-06-03
4
M
false
5000
0.00
D
2029-02-08
Common Stock
5000
14167
D
Includes 361 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023, 460 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2023 and 507 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2024. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
The transaction was made pursuant to a 10b5-1 plan in effect at the time of the transaction.
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $30.17 to $30.21 per share. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.
These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.
The closing price on May 31, 2024 was used to calculate the withholding obligation.
The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on June 3, 2024.
In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.
Fully exercisable.
Chief Accounting & Technology Officer
/s/ Joseph Douglas Lyon
2024-06-05